Home › Ocular Hypertension › NCT05844384

Nanodropper Use in Primary Open-Angle Glaucoma Patients: A Non-Inferiority Trial

Who can join

Ages 18 and older · All sexes

Inclusion Criteria:

* POAG/OHTN patients above the age of 18 years.
* On a maximum of 2 IOP lowering medications.
* Stable disease without progression in IOP, optic disc cupping, RNFL changes, and visual field changes within the previous 1 year.

Exclusion Criteria:

* Glaucoma not of the POAG or OHTN variety or other retinal diseases.
* Progression of disease within the preceding 1 year (IOP elevation, optic disc cupping, visual field changes).
* Using more than 2 IOP-lowering medications.
* IOP-lowering surgical interventions or lasers except for SLT. SLT may have been completed 6+ months prior to study start date.

About the study

This randomized, single-masked, crossover, non-inferiority trial aims to evaluate the safety and efficacy of Nanodropper-mediated microdrops of ocular hypotensive topical treatments (experimental intervention) compared to standard drops of the same medication(s) (active comparator) in Wilford Hall Ambulatory Surgical Center (WHASC) primary open-angle glaucoma (POAG) and ocular hypertension (OHTN) patients.

What is being tested

• Nanodropper (device)
• Regular dropper (device)

Sponsor: 59th Medical Wing · Participants: 30 · Started: Mar 17, 2022

Contact the study team

• Jose E Capo-Aponte, OD, PhD · Phone: 210-292-2554
• Jennifer Steger, PhD · Phone: 507-405-5676

Official record on ClinicalTrials.gov — NCT05844384

Locations in the U.S.

Conditions

• Ocular Hypertension
• Open-Angle Glaucoma

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.